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Calreticulin (CRT) is a chaperone protein which nor-
mally resides in the endoplasmic reticulum (ER). How-
ever, recent studies have demonstrated that pre-
apoptotic cancer cells release internalized CRT to their
surface prior to death, and this surface exposure of CRT
acts as an ‘eat-me’ signal to local phagocytes. Some che-
motherapeutic agents and gamma-irradiation have been
shown to induce ER stress and promote CRT surface
translocation in cancer cells, resulting in their recogni-
tion and phagocytosis by innate immune cells, such as
macrophages and dendritic cells (DC). In turn, innate
immune cells which have phagocytized CRT-expressing
tumor cells become capable of priming antigen-specific
T cell responses directed against malignant cells. Unfor-
tunately, chemotherapy and irradiation which can
induce immunogenic cell death (ICD) through CRT, can
also result in local and/or systemic immune suppression
in the host. To bypass the requirement of exposing the
host to chemotherapy to induce translocation of CRT to
the cell surface, C1498 AML cells were engineered to
constitutively express cell surface CRT (C1498.CRT).
Introduction of C1498.CRT cells subcutaneously (SC)
into syngeneic C57BL/6 mice resulted in either signifi-
cantly delayed tumor outgrowth or complete protection
from tumor development compared to parental C1498
cells which universally progressed in vivo. A SC chal-
lenge with C1498.CRT cells also protected mice from
tumor outgrowth following a subsequent re-challenge
with parental C1498 tumor cells, suggesting that C1498.
CRT cells promote immunologic memory. Differences in
tumor outgrowth between mice inoculated with parental
C1498 and C1498.CRT leukemia cells were abrogated in
immunodeficient RAG-/- and RAG2-/-gc-/- animals,
arguing that the immune-mediated effect of cell-surface
CRT expression is dependent upon a functional adaptive
immune system. To model a clinically relevant scenario,
parental C1498 or C1498.CRT cells were inoculated
intravenously (IV) into C57BL/6 mice. Significantly pro-
longed survival was observed in hosts harboring C1498.
CRT versus parental C1498 cells systemically. Systemic
inoculation with C1498.CRT cells expressing the model
SIYRYYGL (SIY) peptide antigen (C1498.SIY.CRT cells)
resulted in enhanced expansion and effector cytokine
production by antigen-specific T cells compared to T
cells from hosts challenged with control C1498.SIY cells.
Our current on-going experiments are focusing on identi-
fying the mechanism(s) through which calreticulin
appears to promote anti-tumor immunity.
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